https://www.cancerresearchuk.org/about-cancer/treatment/drugs/sotorasib
Sotorasib (Lumykras) | Cancer information | Cancer Research UK
Sotorasib is a targeted cancer drug for the treatment of non small cell lung cancer (NSCLC). Find out about how you have it, possible side effects and other...
cancer informationsotorasibresearchuk
https://www.jadpro.com/education/fda-focus/2025/lumakras-sotorasib-with-vectibix-panitumumab-for-kras-g12c-mutated-colorectal-cancer/
JADPRO | Lumakras sotorasib with Vectibix panitumumab for KRAS G12C-mutated colorectal cancer
colorectal cancersotorasibkrasmutated
https://www.letsmeds.com/sotorasib-120-mg-tablet-price/
sotorasib 120 mg tablet -
Not For Sale Information Purpose Only
sotorasibmgtablet
https://www.lung.org/research/clinical-trials/find-a-clinical-trial/rmc-4630-sotorasib-combo-lung-cancer
Phase 2, Open-Label, Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung...
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 subjects with KRASG12C mutant NSCLC that have not been exposed to...
small cellphaseopenlabelstudy
https://ecancer.org/en/video/9989-safety-of-sotorasib-and-panitumumab-in-advanced-kras-p-g12c-mutated-colorectal-cancer
Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer - ecancer
Dr Marwan Fakih speaks to ecancer in an online interview for the ESMO 2021 meeting about the CodeBreak 101 study. He gives the background of the phase I
colorectal cancersafetysotorasibadvancedkras
https://www.biospace.com/novel-kras-p-g12c-inhibitor-sotorasib-from-amgen-is-the-frontrunner-for-first-fda-approval-in-advanced-non-small-cell-lung-cancer
Novel KRAS p.G12C inhibitor Sotorasib from Amgen is the Frontrunner for First FDA Approval in...
Feb 12, 2021 - The novel mutant KRAS p.G12C inhibitor sotorasib developed by Amgen (AMGN) has demonstrated a high response rate and prolonged progression-free survival in...
fda approvalnovelkrasinhibitorsotorasib